Citigroup
BJDX icon

Citigroup’s Bluejay Diagnostics BJDX Stock Holding History

Citigroup’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60
Closed -$415 – 6092
2025
Q2 		$415 Buy
+60
New +$491 ﹤0.01% 5452

Other funds holding BJDX

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's BJDX Position: Q3 2025 in Review

Citigroup sold out of Bluejay Diagnostics (BJDX) in Q3 2025, closing a stake of 60 shares — an estimated $415 sold.

Citigroup first reported a position in BJDX in Q2 2025 and held it in 1 quarter. The position peaked at $415 in Q2 2025. 4 funds tracked by Wall St. Rank hold BJDX as of Q3 2025.

  • Citigroup reported no remaining Bluejay Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 60 Bluejay Diagnostics shares in Q3 2025, an estimated $415.
  • Citigroup first reported a position in Bluejay Diagnostics in Q2 2025 and held it in 1 quarter.
  • Citigroup's Bluejay Diagnostics position peaked at $415 in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.